Breast Cancer Research and Treatment
Volume 126, Number 1 / February 2011


Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients
Maria Aparecida Nagai, Renê Gerhard, José Humberto T. G. Fregnani, Suely Nonogaki and Regina
Barbosa Rierger, et al.

  • 15-25
    Preclinical study
    Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch
    and NF-κB signaling pathways
    Aamir Ahmad, Zhiwei Wang, Dejuan Kong, Raza Ali and Shadan Ali, et al.
     

  • 27-36
    Preclinical study
    The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells
    Yan Lu, Hua Zhou, Wantao Chen, Yuexing Zhang and Anne W. Hamburger
     

  • 37-45
    Preclinical study
    A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene
    and breast cancer risk
    Ke-Da Yu, Nan-Yan Rao, Ao-Xiang Chen, Lei Fan and Chen Yang, et al.
     

  • 47-54
    Preclinical study
    CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis
    Abdulkader Albasri, Mohammed Aleskandarany, Ahmed Benhasouna, Desmond G. Powe and Ian O. Ellis, et al.
     

  • 55-62
    Preclinical study
    Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines
    Stacy R. Millon, Julie H. Ostrander, J. Quincy Brown, Anita Raheja and Victoria L. Seewaldt, et al.
     

  • 63-71
    Preclinical study
    Role of ferritin alterations in human breast cancer cells
    Svitlana I. Shpyleva, Volodymyr P. Tryndyak, Olga Kovalchuk, Athena Starlard-Davenport and Vasyl’
    F. Chekhun, et al.
     

  • 73-83
    Preclinical study
    Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin
    in affecting breast cancer cell migration
    Konstantin Koro, Stephen Parkin, Brant Pohorelic, An-Dao Yang and Aru Narendran, et al.
     

  • 85-92
    Clinical trial
    Does radiotherapy planning without breath control compensate intra-fraction heart and its
    compartments’ movement?
    Evrim Kadriye Tezcanli, Evren Ozan Goksel, Erdem Yildiz, Melahat Garipagaoglu and Öznur Şenkesen, et al.
     

  • 93-99
    Clinical trial
    Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive
    breast cancer
    Eun-Kyu Kim, Hyun-Ah Kim, Jae Soo Koh, Min Suk Kim and Kwan-Il Kim, et al.
     

  • 101-108
    Clinical trial
    Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or
    metastatic breast cancer
    Nicholas J. Robert, Paul R. Conkling, Mark A. O’Rourke, Paul R. Kuefler and Kristi J. McIntyre, et al.
     

  • 109-117
    Clinical trial
    Comparison of different approaches for assessment of HER2 expression on protein and mRNA level:
    prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
    A. Noske, S. Loibl, S. Darb-Esfahani, M. Roller and R. Kronenwett, et al.
     

  • 119-130
    Clinical trial
    Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia
    Michal Konecny, Miriam Milly, Katarina Zavodna, Eva Weismanova and Jaroslava Gregorova, et al.
     

  • 131-140
    Epidemiology
    Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics
    Elrasheid A. H. Kheirelseid, Hanzali Jumustafa, Nicola Miller, Catherine Curran and Karl Sweeney, et al.
     

  • 141-148
    Epidemiology
    Association between polymorphisms of the ataxia telangiectasia mutated gene and breast cancer risk:
    evidence from the current studies
    Pei-Hua Lu, Mu-Xin Wei, Shu-Ping Si, Xiao Liu and Wei Shen, et al.
     

  • 149-155
    Epidemiology
    Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor
    status: results from a prospective cohort study
    Aditya Bardia, Janet E. Olson, Celine M. Vachon, DeAnn Lazovich and Robert A. Vierkant, et al.
     

  • 157-165
    Epidemiology
    Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western
    New York Exposures and Breast Cancer (WEB) Study
    Theodore M. Brasky, Matthew R. Bonner, Kirsten B. Moysich, Heather M. Ochs-Balcom and Catalin
    Marian, et al.
     

  • 167-176
    Epidemiology
    Effects of breast cancer surgery and surgical side effects on body image over time
    Karen Kadela Collins, Ying Liu, Mario Schootman, Rebecca Aft and Yan Yan, et al.
     

  • 177-183
    Epidemiology
    Association between polymorphisms of trinucleotide repeat containing 9 gene and breast cancer risk:
    evidence from 62,005 subjects
    Min-Bin Chen, Xiao-Yang Wu, Wei Shen, Mu-Xin Wei and Chen Li, et al.
     

  • 185-192
    Epidemiology
    Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study
    Shaheenah Dawood, Rong Hu, Michelle D. Homes, Laura C. Collins and Stuart J. Schnitt, et al.
     

  • 193-202
    Epidemiology
    Body weight and risk of breast cancer in BRCA1/2 mutation carriers
    Peggy Manders, Anouk Pijpe, Maartje J. Hooning, Irma Kluijt and Hans F. A. Vasen, et al.
     

  • 203-209
    Brief Report
    The RING heterodimer BRCA1–BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs
    Apichart Atipairin, Bhutorn Canyuk and Adisorn Ratanaphan
     

  • 211-214
    Brief Report
    Invasive ductal breast cancer associated polymyositis causing respiratory failure
    Xi Li, Wanshou Qiu, Yong Huang, Juekun Wu and Renbin Liu
     

  • 215-220
    Brief Report
    Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing
    of anti-cancer agents
    Pamela J. Goodwin, Vuk Stambolic, Julie Lemieux, Bingshu E. Chen and Wendy R. Parulekar, et al.
     

  • 221-226
    Brief Report
    Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant
    endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Kelly-Anne Phillips, Julie Aldridge, Karin Ribi, Zhuoxin Sun and Alastair Thompson, et al.
     

  • 227-230
    Brief Report
    Germline mutations in PALB2 in African-American breast cancer cases
    Yuan Chun Ding, Linda Steele, Li-Hao Chu, Karen Kelley and Helen Davis, et al.
     

  • 231-234
    Brief Report
    Reversed urban–rural differences in breast cancer mortality (China, 2002–2008)
    Min He, Qulian Guo and Guoqing Hu
     

  • 235-239
    Brief Report
    No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer
    risk in Caucasian women
    Jonathan Beesley, Sharon E. Johnatty, Xiaoqing Chen, Amanda B. Spurdle and Paolo Peterlongo, et al.
     

  • 241-245
    Letter to the Editor
    Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine
    carcinomas of the breast
    Eugeni Lopez-Bonet, Maria Carmen Pérez-Martínez, Begoña Martin-Castillo, Miguel Alonso-Ruano
    and Francesc Tuca, et al.
     

  • 247-248
    Letter to the editor
    Comments on: Iwasaki et al. Fragment c gamma receptor gene polymorphisms and breast cancer risk in
    case–control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians
    Janardan P. Pandey
     

  • 249-252
    Letter to the Editor
    A small number of subjects do not always indicate that they are minor variants data for inclusion in a
    pooled analysis
    Pei-Hua Lu, Min-Bin Chen, Mu-Xin Wei, Zhi-Yang Jiang and Chen Li
     

  • 253-256
    Letter to the Editor
    Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: appraisal of a recent meta-analysis
    Ping Zhou, Jian-Ping Li and Chun Zhang
     

  • 257-259
    Letter to the Editor
    No association of polymorphisms in the cell polarity gene SCRIB with breast cancer risk in German population
    Chun Zhang, Ping Zhou and Jian-Ping Li
     

  • 261-262
    Letter to the Editor
    Effects of breast cancer surgery and surgical side effects on body image over time
    Alexandre Mendonça Munhoz, Rolf Gemperli and José Roberto Filassi
     

  • 263-264
    REBUTTAL LETTER
    Effects of breast cancer surgery and surgical side effects on body image over time
    Karen Kadela Collins, Maria Pérez, Mario Schootman, Rebecca Aft and Donna B. Jeffe
     

  • 265-266
    Letter to the Editor
    New conflicting results obtained in the subgroup analysis of RAD51 135G>C polymorphism and breast
    cancer risk
    Pei-Hua Lu, Min-Bin Chen, Wei Shen, Chen Li and Ming-Yu Wu, et al.
     

  • 267
    Erratum
    A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early
    breast carcinoma
    Steven Sugarman, Carolyn Wasserheit, Elizabeth Hodgman, Maryellen Coglianese and Anne D’Alassandro,
    et al.
     

  • 269
    Erratum
    Erratum to: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in
    BRCA2- associated tumors
    Anita L. Bane, Dushanthi Pinnaduwage, Sarah Colby, Michael Reedijk and Sean E. Egan, et al.
     

  • 271-272
    Erratum
    Erratum to: The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a
    controlled longitudinal study
    Felice A. Tager, Paula S. McKinley, Freya R. Schnabel, Mahmoud El-Tamer and Ying Keun K. Cheung, et al.

 
 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     
     
     
 

 

آدرس: تهران، خیابان سهروردی شمالی، خیابان هویزه شرقی، ساختمان 43، طبقه اول، واحد3، کدپستی، 1558619794

تلفن / فکس: 88506456 - 88506457 (21) (+98)

صندوق پستی: 1313 - 13335

ایمیل: p.surgeons@yahoo.com